Konakion

Phytomenadione, the active ingredient in Konakion, is a Vitamin K presented as a pharmaceutical preparation for intravenous and oral use. It is employed to correct vitamin K deficiency–related bleeding and to reverse the effects of warfarin anticoagulation.\n\nGNH India supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konakion is a vitamin K agent used to manage disorders of coagulation caused by deficiency or antagonism.\n\n- Prevention and treatment of hemorrhage due to vitamin K deficiency: restores clotting factor activity and stops bleeding.\n- Reversal of over‑anticoagulation caused by warfarin: normalizes coagulation parameters and reduces bleeding risk.\n- Neonatal prophylaxis against vitamin K deficiency bleeding: prevents hemorrhagic disease in newborns.

Adverse reactions may occur with Konakion administration.\n\nCommon Side Effects:\n- Injection site pain\n- Redness or swelling at the site\n- Fever or chills\n- Nausea or vomiting\n- Headache\n\nSerious or Rare Side Effects:\n- Anaphylactic reaction\n- Severe bleeding despite therapy\n- Thrombosis or clot formation\n- Hypotension\n- Acute hemolysis

Use Konakion with caution and observe clinical monitoring.\n\n- Pregnancy: safety unknown; administer only if benefits outweigh potential risks.\n- Breastfeeding: unknown safety; consider discontinuation if adverse effects observed in infant.\n- Renal impairment: monitor coagulation status closely.\n- Concomitant anticoagulant therapy: adjust dosing and monitor for over‑correction.\n- Known hypersensitivity: discontinue immediately if allergic reaction occurs.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Konakion may interact with other medications affecting coagulation.\n\nMajor Interactions (Avoid):\n- Warfarin: may reduce anticoagulant effect, leading to sub‑therapeutic levels.\n- Broad‑spectrum antibiotics (e.g., cephalosporins): can interfere with vitamin K metabolism.\n- Other vitamin K antagonists: concurrent use may diminish reversal efficacy.\n\nModerate Interactions (Monitor Closely):\n- Heparin: additive anticoagulant effect may increase bleeding risk.\n- Platelet inhibitors (e.g., clopidogrel): may enhance bleeding tendencies.